Welcome to the website of the AmbuLung project



A milestone in the evolution of artificial organs

Work Packages and Deliverables of the project


AmbuLung focuses on designing, testing, and implementing a novel bioartificial device, a miniaturized ambulatory extracorporeal respiratory unit that will be lined with endothelial cells to improve the gas exchange and prevent thromboembolic complications.

These improvements will in turn lead to enhanced durability and patient compatibility. Accordingly, the work to be performed comprises both engineering and biological/biomedical components and entails a close collaboration between an SME and three premier academic research centers in Europe,

The project is beeing carried out in eight work packages (WP). Two work packages are purely engineering-oriented, four work packages comprise biologic, biotechnological, biomedical and computational goals and all require close interdisciplinary collaborations between all the teams. The remaining two work packages focus on Dissemination, Exploitation, Management and Coordination respectively.


In this engineering WP (Novalung), we miniaturize and validate the gas exchange membrane for AmbuLung. The tasks include redesigning the gas exchange fiber configuration, and modifications to the fiber surfaces for optimizing cell adhesion and gas exchange as predicted from novel computational models. Entailed in this WP is also the task to redesign the vascular access to improve performance of the unit.


In this engineering WP (Novalung) we miniaturize and validate the hardware components and peripheral electronic controls for the miniaturized gas exchange unit (WP1), and hence create a truly ambulatory self-sufficient extracorporeal respiratory system.


In this biological/biotechnological WP (Imperial) we use information-driven bioprocesses and established computational models to optimize bioreactor - technologies to expand the number of human embryonic stem cells and their directed differentiation into vascular endothelial and pulmonary epithelial cells. These are then tested in vitro (WP4) and in vivo (WP5).


In this biological/technological WP (Fraunhofer) computational modeling in silico and novel physicochemical surface modifications are used to optimize cell-biomaterials interactions. The functionality of the cellular monolayers lining the prototypes of the miniaturized gas exchange unit (WP1) and their shear resistance/durability are tested in vitro using dynamic bioreactors.


The focus of this preclinical WP (Novalung) is to test the efficacy and safety of the cell-lined prototype gas exchange units, both in silico, extending the computational model of thrombogenicity and platelet adhesion developed in WP4, as well as in vivo in a animal model of chronic respiratory distress.


The focus of this clinical WP (UNIFI) is to secure the necessary Institutional Review Board (IRB) approval and to carry out a small-scale first-in-man clinical trial of AmbuLung at the end of the project in order to obtain clinical trial authorization.


This non-scientific WP (all partners) is orientated towards publishing all information, knowledge and results generated by this project to society and to ensure exploitation of a marketable AmbuLung product.


As the Project Coordinator Novalung ensures and supports an efficient internal management of AmbuLung and undertakes a timely and efficient communication between the coordination core and the European Commission. A robust management plan is implemented to ensure shared accountability of the overall goals of the project and that these are met accordingly.

To top

This project is funded by the European Union EU-Flagge sfp